Get Exposure to the Companies Leading Vaccine Development

The ongoing COVID-19 pandemic has demonstrated that vaccines are an essential tool in protecting global populations and have led to the near-eradication of life-threatening illnesses such as Smallpox and Polio. By safeguarding the public, vaccines help ensure that people can continue to work and supply chains continue to move, highlighting their value preserving and protecting the global economy.

The life sciences and pharmaceutical companies that develop these treatments are also benefitting. Due to the renewed importance of vaccines, cutting-edge therapies and pandemic preparedness the healthcare sector has received massive capital infusions, which could potentially propel further transformative innovation.

The Horizons Global Vaccines and Infectious Diseases Index ETF (HVAX), allows investors to gain exposure to the potentially long-term theme of vaccine development and disease prevention.

HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.
A Renewed Focus on Disease Prevention

There are four key areas of healthcare research and development that will aid in preventing future global pandemics or potentially eradicating existing infectious diseases.

**Vaccines:** Vaccine development is a key focus of healthcare research and development (R&D) and the primary science-based technology available to combat infectious diseases. By 2024, the global vaccines market is projected to reach $58.4 billion at a CAGR of 7.0%*. The growth is attributed to the high prevalence of infectious diseases, increasing company initiatives to enhance vaccine R&D, growing government support for vaccine development and the rising focus on immunization.

**Diagnostics:** Diagnostics in the prevention and identification of diseases is arguably just as crucial a line of defense against infectious disease as vaccines.

**Therapeutics:** This is part of the industry focused on key pharmaceutical treatments such as antiviral drugs or important biotechnology treatments such as antibodies. This has been a key area of growth as researchers look to find drug or clinical treatments that can be used to help prevent mortality and symptoms of disease.

**Genomics:** Genomics focuses on DNA and genetic research to create more effective therapeutic treatments. This area of study was a key determinant in the development of Pfizer/BioNTech and Moderna mRNA vaccine technology.

*Source: [https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html](https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html)

**Key Features**

- Provides globally diversified exposure to leading companies that provide research, medicines and vaccines against infectious diseases
- Massive public and private investment during COVID-19 pandemic driving exciting innovation in vaccine and pharmaceutical development
- COVID-19 has likely created a long-term focus on global disease prevention, a potentially long-term trend
- Substantial revenue opportunities from further vaccine and infectious disease development beyond COVID-19
The Solactive Global Vaccines and Infectious Diseases Index (the “Underlying Index”), is designed to provide exposure to the performance of global, publicly-listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics.

Constituents issuers will be drawn from publicly listed companies in developed and emerging markets, and may include small, mid and large-capitalization companies. The Underlying Index will not include securities that trade on the Shanghai and Shenzhen Connect exchanges but may include securities which have Hong-Kong listed shares or ADRs. In addition, a company must meet minimum trading, liquidity and market capitalization requirements to be considered for inclusion.

The Underlying Index uses an innovative natural language processing algorithm, known as ARTIS, a proprietary tool of Solactive, which is built to identify thematic exposure in corporations using unconventional data sources. ARTIS uses keywords to identify companies that have or are expected to have significant exposure in the theme of involvement in the development and production of vaccines, therapeutics and diagnostics.

To learn more, please visit www.HorizonsETFs.com/ETF/HVAX